Companion Animals

Transitional Cell Carcinoma in Dogs: Welfare and Management

Managing bladder cancer in dogs through pain control and targeted therapy to maintain quality of life.

Key Facts

TCC is the most common bladder tumour in dogs — Scottish Terriers have 18x elevated risk
Causes haematuria, straining to urinate, and recurrent urinary infection
Piroxicam alone provides welfare improvement in many dogs without significant side effects
Targeted therapy with toceranib plus piroxicam improves outcomes in some cases

Welfare Considerations

Transitional cell carcinoma causes significant welfare compromise through dysuria, haematuria, and urinary obstruction in advanced cases. Welfare-centred management prioritises pain control and maintaining urinary function. Piroxicam is a welfare-improving palliative option with minimal toxicity — most dogs show improved comfort within 2-4 weeks. Honest prognostic discussion enables owners to make informed welfare-centred decisions.

What You Can Do

Investigate any Scottish Terrier or other at-risk breed with haematuria promptly
Start piroxicam promptly after diagnosis — welfare improvement is rapid
Discuss prognosis honestly and use quality of life scoring to guide ongoing management decisions